LPL Financial LLC Has $15.47 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

LPL Financial LLC grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 17.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 242,432 shares of the biopharmaceutical company's stock after purchasing an additional 35,429 shares during the period. LPL Financial LLC owned approximately 0.20% of Halozyme Therapeutics worth $15,470,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of HALO. Snyder Capital Management L P grew its holdings in Halozyme Therapeutics by 2.6% during the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock worth $199,294,000 after acquiring an additional 105,086 shares in the last quarter. Congress Asset Management Co. increased its holdings in Halozyme Therapeutics by 8.8% in the first quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company's stock valued at $136,088,000 after buying an additional 172,971 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Halozyme Therapeutics by 2.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock valued at $92,446,000 after buying an additional 47,795 shares during the last quarter. Northern Trust Corp raised its stake in Halozyme Therapeutics by 8.7% during the fourth quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock valued at $87,386,000 after buying an additional 145,617 shares in the last quarter. Finally, TD Asset Management Inc lifted its holdings in Halozyme Therapeutics by 5.8% during the 1st quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company's stock worth $92,642,000 after buying an additional 79,708 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $0.80 on Friday, reaching $62.90. 1,592,672 shares of the stock were exchanged, compared to its average volume of 1,955,975. The company has a current ratio of 8.36, a quick ratio of 7.30 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.50. The firm has a fifty day moving average price of $55.84 and a two-hundred day moving average price of $57.88. The stock has a market cap of $7.75 billion, a PE ratio of 14.39, a PEG ratio of 0.42 and a beta of 1.17.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. During the same quarter in the previous year, the firm posted $0.91 earnings per share. Halozyme Therapeutics's revenue was up 40.8% compared to the same quarter last year. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at approximately $41,403,763.17. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 60,000 shares of company stock worth $3,262,400. 2.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on HALO. Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target on the stock. in a research report on Tuesday, May 13th. Morgan Stanley raised shares of Halozyme Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $62.00 to $75.00 in a report on Wednesday. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price objective on the stock. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, JMP Securities boosted their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $66.56.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.